PharmaCorp Rx — Capital/Financing Update 2025

Nov 8, 2025

DLA PIPER

DLA Piper (Canada) LLP
Suite 1000, Livingston Place West
250 2nd St SW
Calgary AB T2P 0C1
www.dlapiper.com

DLA Piper (Canada) LLP
T
F 403.296.4474

November 7, 2025

VIA SEDAR+

Financial and Consumer Affairs Authority of Saskatchewan
British Columbia Securities Commission
Alberta Securities Commission
Manitoba Securities Commission
Ontario Securities Commission
Financial and Consumer Services Commission of New Brunswick
Nova Scotia Securities Commission
Office of the Superintendent of Securities, Prince Edward Island
Government of Newfoundland and Labrador Financial Services Regulation Division

Dear Sirs/Mesdames:

Re: PharmaCorp Rx Inc. - Prospectus Supplement

We refer to the prospectus supplement (the "Supplement") of PharmaCorp Rx Inc. (the "Corporation") dated November 7, 2025, to the final short form base shelf prospectus of the Corporation dated October 7, 2025 relating to the sale of units of the Corporation.

We hereby consent to the references to our name, DLA Piper (Canada) LLP on the cover page and under the heading "Legal Matters" in the Supplement and to the use of our name, DLA Piper (Canada) LLP, and our opinions under the headings "Eligibility for Investment" and "Certain Canadian Federal Income Tax Considerations" in the Supplement, which opinions are provided as of the date of the Supplement.

We confirm that we have read the Prospectus and that we have no reason to believe that there are any misrepresentations in the information contained in the Prospectus that are derived from our opinions in the Prospectus or that are within our knowledge as a result of the services we performed in the preparation of the Prospectus.

Sincerely,

DLA Piper (Canada) LLP

(signed) "DLA Piper (Canada) LLP"